Introduction to ESMO 2025 Genitourinary Cancer Abstracts
ESMO 2025 genitourinary cancer abstracts show exciting new finds. For instance, they include a 78% rPFS boost in prostate studies. In addition, these works cover prostate, bladder, and kidney cancers. Experts ranked them by impact, trial stage, new ideas, and care changes. Moreover, the list comes from @OncoAlert. Now, let’s look at them.
#10: DISCUS Trial Cuts Chemo Load
The DISCUS trial checks 3 versus 6 chemo rounds before avelumab in urothelial cancer. For example, it signed up about 300 patients. In addition, it lowers chemo by 50%. Therefore, it reduces treatment strain. However, its phase 2 status limits quick wide use. Still, avelumab gives OS HR 0.69.
#9: BladderPath Boosts Staging
A bladder cancer MRI scan.
BladderPath tests MRI against resection for bladder staging. For instance, it signed up 350 patients. Moreover, MRI reaches 81% accuracy for MIBC versus NMIBC. In addition, it cuts treatment time by 13 days. Therefore, it gives a less invasive choice.
#8: CAPItello-281 Moves Precision Forward
CAPItello-281 adds capivasertib to abiraterone in PTEN-lacking mHSPC. It signed up 1,012 patients. For example, it boosts rPFS a lot. About 20% of mHSPC cases move to CRPC on abiraterone alone. Thus, this steps up precision care.
#7: Disitamab Vedotin Mix Stands Out
This trial sets disitamab vedotin and toripalimab against chemo in HER2+ urothelial cancer. In addition, prior data show 73.2% ORR and 90.2% DCR. The phase 3 hit PFS and OS goals. Therefore, it opens more choices beyond chemo.
#6: RAMPART Improves RCC Care
RAMPART checks durvalumab alone or with tremelimumab after RCC surgery. It signed up 1,500 patients. Moreover, it shows a 5-year DFS HR of 0.75 against placebo. Without added therapy, return risk is about 40%. Thus, it tackles after-surgery care talks.
#5: ENZARAD Betters Prostate Results
Prostate cancer cells under a microscope.
ENZARAD adds enzalutamide to ADT and radiation in high-risk prostate cancer. For example, it signed up 500 patients with median age 71. In addition, it gives an MFS HR of 0.68. Base 5-year MFS with ADT plus RT alone is about 60%. Therefore, it meets key needs.
#4: IMvigor011 Leads with ctDNA
IMvigor011 uses ctDNA to guide atezolizumab in MIBC. It signed up about 760 patients. Moreover, in ctDNA+ groups, DFS HR is 0.45 and OS HR 0.52. ctDNA positive raises return risk by 50%. Thus, this moves toward custom care.
#3: KEYNOTE-905 Aims at Cisplatin-Unfit
KEYNOTE-905 tests enfortumab vedotin plus pembrolizumab in cisplatin-unfit MIBC. For instance, it signed up over 1,000 patients. It hits a 37% pCR rate. In addition, EFS HR is 0.47 and OS HR 0.55 against cystectomy. Therefore, it changes rules for weak groups.
#2: EMBARK Gives OS Info
EMBARK shares OS data with enzalutamide in returning prostate cancer. It signed up 1,068 high-risk patients. Moreover, OS HR is 0.71 against leuprolide alone. MFS HR is 0.42. 5-year OS hits about 85% in enzalutamide groups. Thus, it shapes early action.
#1: PSMAaddition – A Big Shift
PSMAaddition mixes Lu-PSMA-617 with ADT and ARPI in PSMA-positive mHSPC. It signed up 1,200 patients. For example, 12-month rPFS is 78% versus 62% in control. rPFS HR is 0.52. Because of VISION trial backing, it proves front-line use.
Expert Views on Therapy Effects
These ESMO 2025 genitourinary cancer abstracts cover treatments with possible heart risks. However, Javid Moslehi, MD, UCSF, points out issues. For instance, “I’m a clinical cardiologist who’s interested in cardiovascular health of cancer patients, specifically prostate cancer patients.” In addition, he notes, “So for example, we know androgen deprivation therapy with GnRH agonists can have adverse cardiovascular effects.” Therefore, team care matters.
Why These Abstracts Count
These ESMO 2025 genitourinary cancer abstracts aim to reshape care. From less treatment to front-line new ideas, they bring hope. Moreover, go to ESMO 2025 in Berlin, October 17-21. Share with #ESMO2025. Thanks to @OncoAlert for the tips.